Ceftriaxone reduces L-dopa–induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model

Keyphrases

• 6-hydroxydopamine (6-OHDA) 100%
• 6-hydroxydopamine Lesion 11%
• Abnormal Involuntary Movements 11%
• Ceftriaxone 100%
• Consecutive Days 11%
• Dyskinesia 100%
• Extracellular Glutamate 11%
• Glutamate Receptors 11%
• Glutamate Transporter 1 (GLT-1) 33%
• Glutamate Uptake 33%
• Glutamatergic Neurotransmission 11%
• L-DOPA 100%
• Levodopa-induced Dyskinesia 11%
• Motor Impairment 11%
• Once-daily 11%
• Parkinson Patients 11%
• Parkinson's Disease Model 100%
• Partial Recovery 11%
• Spontaneous Excitatory Postsynaptic Current (sEPSC) 11%
• Striatal 33%
• Striatal Lesion 44%
• Therapeutic Strategies 11%
• Time Prior 11%
• Tyrosine Hydroxylase 33%
• Uptake Transporter 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Ceftriaxone 100%
• Disease Model 100%
• Dyskinesia 100%
• Glutamate Receptor 10%
• Glutamate Transporter 10%
• Glutamic Acid 40%
• Levodopa 100%
• Motor Dysfunction 10%
• Oxidopamine 100%
• Parkinson's Disease 100%
• Side Effect 20%
• Tyrosine 3 Monooxygenase 30%

Neuroscience

• Ceftriaxone 100%
• Dyskinesia 100%
• Glutamate Receptor 10%
• Glutamate Transporter 10%
• Glutamic Acid 40%
• L-DOPA 100%
• Neurotransmission 10%
• Oxidopamine 100%
• Parkinson's Disease 100%
• Stereotypic Movement Disorder 10%
• Tyrosine Hydroxylase 30%